Oncology Drug Pricing Appears Unrelated To Novelty, Benefit – NCI Review
This article was originally published in The Pink Sheet Daily
Executive Summary
A review of oncology drug approvals from 2009 through 2013 suggests that “current pricing models are not rational but simply reflect what the market will bear,” researchers conclude in a letter published in JAMA Oncology.